ARGX vs CAH

ARGX demonstrates strong financial health with a Piotroski F-Score of 6/9, indicating stable fundamentals despite a lack of Altman Z-Score. The company exhibits exceptional revenue growth (74.6% YoY) and a robust profit margin (30.42%), supported by a near-zero debt-to-equity ratio and high liquidity. While earnings declined YoY (-32%), this is likely due to one-time R&D investments and a prior-year anomaly, as evidenced by a massive 856.3% YoY EPS growth and consistent earnings surprises. The stock trades at a premium to its Graham Number ($228.72) and intrinsic value ($137.2), but this is justified by its high growth trajectory and strong analyst consensus. The 52-week price range suggests significant upside potential from current levels.

Cardinal Health presents a dichotomy of strong growth and fragile liquidity, anchored by a stable Piotroski F-Score of 4/9. While the company exhibits impressive YoY revenue and earnings growth (~19%) and consistently beats analyst estimates, its operational health is hampered by razor-thin profit margins (0.68%) and a concerning current ratio of 0.91. The stock is trading slightly below its intrinsic value of $205.03, but bearish insider activity and a 0/100 technical trend suggest immediate headwinds despite a 'strong_buy' analyst consensus.